FDA Approves First Treatment for Rare Eye Disease
\n——————————–
\nThe FDA has approved ENCELTO, the first-ever treatment for macular telangiectasia type 2 (MacTel), a rare disease that gradually robs people of central vision, SciTech Daily reported.<\/p>\n
ENCELTO is a small implant placed at the back of the eye that steadily releases a protective protein to slow the loss of light-sensing retinal cells. Two phase 3 clinical trials, conducted over 24 months at 47 sites worldwide with 228 patients, showed a 31\u201355% reduction in cell damage compared with untreated eyes. The device also helped preserve retinal function, with the greatest benefits seen when treatment began early.<\/p>\n
ENCELTO\u2019s approval marks the first cell-based neuroprotective therapy for any degenerative retinal or central nervous system disease and could serve as a model for treating other vision and nerve disorders.<\/p>\n","protected":false},"excerpt":{"rendered":"
FDA Approves First Treatment for Rare Eye Disease ——————————– The FDA has approved ENCELTO, the first-ever treatment for macular telangiectasia type 2 (MacTel), a rare disease that gradually robs people of central vision, SciTech Daily reported. ENCELTO is a small implant placed at the back of the eye that steadily releases a protective protein to …<\/p>\n","protected":false},"author":1,"featured_media":132713,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"facebook_108372464460192_245495985553329":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[8955],"tags":[],"class_list":["post-132714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-news"],"yoast_head":"\n